Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the American Geriatrics Society
- PMID: 40250966
- DOI: 10.1016/j.jacl.2024.09.005
Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the American Geriatrics Society
Abstract
The risk of atherosclerotic cardiovascular disease increases with advancing age. Elevated low-density lipoprotein (LDL)-cholesterol and non-high-density lipoprotein (non-HDL)-cholesterol levels remain predictive of incident atherosclerotic cardiovascular events among individuals older than 75 years. Risk prediction among older individuals is less certain because most current risk calculators lack specificity in those older than 75 years and do not adjust for co-morbidities, functional status, frailty, and cognition which significantly impact prognosis in this age group. Data on the benefits and risks of lowering LDL-cholesterol with statins in older patients without atherosclerotic cardiovascular disease are also limited since most primary prevention trials have included mostly younger patients. Available data suggest that statin therapy in older primary prevention patients may reduce atherosclerotic cardiovascular events and that benefits from lipid-lowering with statins outweigh potential risks such as statin-associated muscle symptoms and incident type 2 diabetes mellitus. While some evidence suggests the possibility that statins may be associated with incident cognitive impairment in older adults, a preponderance of literature indicates neutral or even protective statin-related cognitive effects. Shared decision-making which is recommended for all patients when considering statin therapy is particularly important in older patients. Randomized clinical trial data evaluating the use of non-statin lipid-lowering therapy in older patients are sparse. Deprescribing of lipid-lowering agents may be appropriate for select patients older than 75 years with life-limiting diseases. Finally, a patient-centered approach should be taken when considering primary prevention strategies for older adults.
Keywords: Hypercholesterolemia; Older adult; Primary prevention.
Copyright © 2024. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest VB received research support from Amgen, DalCor, Esperion, Novartis, Sanofi and from the National Institute on Aging via subcontract from Atrium Health/Wake Forest University; is a data safety monitoring board member for Eli Lilly and Verve Therapeutics; and attended an advisory board for New Amsterdam Pharma. SAL has no disclosures. DLD received research funding from Boehringer Ingelheim. DEF received research funding from the National Institute on Aging, Veterans Health Administration, and the Patient-Centered Outcomes Research Institute. ARG received research support from the National Institute on Aging and the National Institute on Aging IMbedded Pragmatic Alzheimer's disease and AD-Related Dementias Clinical Trials Collaboratory. TAJ has no disclosures. ARO received funding from the National Institute on Aging and the Department of Veterans Affairs. JJS was a data safety monitoring board member for Amgen. SSV received research support from National Institutes of Health, United Kingdom National Institutes for Health and Care Research, Department of Veterans Affairs, Tahir and Jooma Family, and Asharia Family.
Similar articles
-
Managing Hypercholesterolemia in Adults Older Than 75 years Without a History of Atherosclerotic Cardiovascular Disease: An Expert Clinical Consensus From the National Lipid Association and the American Geriatrics Society.J Am Geriatr Soc. 2025 Jun;73(6):1674-1696. doi: 10.1111/jgs.19398. Epub 2025 Apr 10. J Am Geriatr Soc. 2025. PMID: 40207842 Free PMC article.
-
Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?Curr Atheroscler Rep. 2024 Sep;26(9):521-536. doi: 10.1007/s11883-024-01224-4. Epub 2024 Jul 3. Curr Atheroscler Rep. 2024. PMID: 38958924 Review.
-
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.J Am Coll Cardiol. 2017 Oct 3;70(14):1785-1822. doi: 10.1016/j.jacc.2017.07.745. Epub 2017 Sep 5. J Am Coll Cardiol. 2017. PMID: 28886926
-
Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort.Curr Med Res Opin. 2024 Jan;40(1):15-25. doi: 10.1080/03007995.2023.2270901. Epub 2024 Jan 3. Curr Med Res Opin. 2024. PMID: 37941428
-
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.Drugs. 2004;64(11):1181-96. doi: 10.2165/00003495-200464110-00003. Drugs. 2004. PMID: 15161326 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical